Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			$ 80		$ 394
Weighted-average useful life of intangible assets			7 years 10 months 14 days
Amortization expense of intangible assets	$ 400	$ 100	$ 800	$ 300
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			100
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired					$ 400
Acquired finite-lived intangible assets, amortization period					12 years 9 months
Licensing Agreements | Gland Pharma Ltd
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 1,600		$ 2,700
Acquired finite-lived intangible assets, amortization period			5 years		5 years
Customer List | Athenex Pharma Solutions
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					12 years